Byoung Chul Cho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5058622/publications.pdf

Version: 2024-02-01

340 papers	26,028 citations	14655 66 h-index	8167 148 g-index
345 all docs	345 docs citations	345 times ranked	21404 citing authors

#	Article	IF	Citations
1	Osimertinib in UntreatedEGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	27.0	3,530
2	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	13.7	2,347
3	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	27.0	1,725
4	Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonâ€“small cell lung cancer harboring EGFR T790M. Nature Medicine, 2015, 21, 560-562.	30.7	1,280
5	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 1506-1517.	10.7	767
6	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2021, 398, 759-771.	13.7	642
7	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3290-3297.	1.6	515
8	Tepotinib in Nonâ€“Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine, 2020, 383, 931-943.	27.0	500
9	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 661.	7.1	446
10	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1301-1311.	1.6	445
11	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 822-835.	10.7	390
12	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCâ€”Update from PACIFIC. Journal of Thoracic Oncology, 2020, 15, 288-293.	1.1	328
13	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of AlectinibÂinÂUntreated ALK-Positive Advanced Nonâ€“Small CellÂLung Cancer in the Global Phase III ALEX Study. Journal of Thoracic Oncology, 2019, 14, 1233-1243.	1.1	324
14	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discovery, 2018, 8, 1227-1236.	9.4	321
15	Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402.	1.6	320
16	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 261-270.	10.7	303
17	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncology, The, 2020, 21, 373-386.	10.7	300
18	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Nonâ€“Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Journal of Clinical Oncology, 2017, 35, 2613-2618.	1.6	260

#	Article	IF	Citations
19	Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treatment Reviews, 2018, 65, 1-10.	7.7	225
20	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncology, The, 2021, 22, 959-969.	10.7	222
21	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. Journal of Clinical Oncology, 2020, 38, 538-547.	1.6	221
22	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Scientific Reports, 2016, 6, 36956.	3.3	196
23	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â€'Positive, Advanced Nonâ€'Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 2020, 38, 1580-1590.	1.6	189
24	Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Nonâ€“Small Cell Lung Cancer with T790M Resistance Mutation. Molecular Cancer Therapeutics, 2012, 11, 2254-2264.	4.1	179
25	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. Journal of Clinical Oncology, 2020, 38, 9503-9503.	1.6	179
26	Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. Gastroenterology, 2017, 153, 191-204.e16.	1.3	158
27	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFRâ€“MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertionâ€“Driven NSCLC. Cancer Discovery, 2020, 10, 1194-1209.	9.4	158
28	Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 731-737.	1.6	154
29	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncology, The, 2022, 23, 781-792.	10.7	150
30	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) â‰¥ 1%: Open-label, phase 3 KEYNOTE-042 study.. Journal of Clinical Oncology, 2018, 36, LBA4-LBA4.	1.6	146
31	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Nonâ€“Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, 1357-1367.	1.1	144
32	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€“Positive Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1718-1732.	1.1	141
33	Phase II Study of Erlotinib in Advanced Nonâ€“Small-Cell Lung Cancer After Failure of Gefitinib. Journal of Clinical Oncology, 2007, 25, 2528-2533.	1.6	140
34	Distinct clinical features and outcomes in neverâ€smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer, 2012, 118, 729-739.	4.1	132
35	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncology, 2019, 15, 1057-1066.	2.4	132
36	Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung Cancer, 2018, 115, 12-20.	2.0	131

#	Article	IF	Citations
37	Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2019, 20, 1454-1466.	10.7	125
38	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1670-1680.	10.7	125
39	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer, 2016, 97, 73-80.	2.0	122
40	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 1379-1388.	10.7	119
41	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Î² and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1210-1222.	1.1	119
42	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology, 2021, 16, 1547-1558.	1.1	108
43	Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types. Cancer Immunology Research, 2018, 6, 87-97.	3.4	106
44	A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. Journal of Molecular Diagnostics, 2014, 16, 229-243.	2.8	105
45	Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmallâ€cell lung cancer. Cancer, 2010, 116, 1336-1343.	4.1	99
46	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Experimental and Molecular Medicine, 2020, 52, 1550-1563.	7.7	99
47	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 505-521.	3.0	97
48	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine,the, 2017, 5, 891-902.	10.7	92
49	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1â€“2 study. Lancet Oncology, The, 2019, 20, 1681-1690.	10.7	92
50	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15â€year experience at a single institute. Journal of Surgical Oncology, 2007, 95, 461-468.	1.7	89
51	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discovery, 2019, 9, 384-395.	9.4	88
52	High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 2426-2432.	7.0	85
53	The Ratio of Peripheral Regulatory T Cells to Lox-1⁺ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Antiâ€“PD-1 Therapy in Patients with Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 243-246.	5.6	85
54	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Journal of Thoracic Oncology, 2019, 14, 99-106.	1.1	82

#	Article	IF	Citations
55	Glycolysis Inhibition Sensitizes Nonâ€“Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation. Molecular Cancer Therapeutics, 2013, 12, 2145-2156.	4.1	80
56	Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1065-1073.	0.8	79
57	Bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
58	Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer, 2011, 72, 9-15.	2.0	78
59	Characteristics and Outcome of ROS1-Positive Nonâ€“Small Cell Lung Cancer Patients in Routine Clinical Practice. Journal of Thoracic Oncology, 2018, 13, 1373-1382.	1.1	77
60	Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cellular Immunology, 2012, 278, 76-83.	3.0	75
61	Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 487-492.	1.6	74
62	Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Medicine, 2015, 7, 98.	8.2	74
63	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 1253-1263.	1.6	74
64	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9009-9009.	1.6	74
65	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical Cancer Research, 2022, 28, 1302-1312.	7.0	74
66	Efficacy and safety of dovitinib in pretreated patients with advanced squamous nonâ€small cell lung cancer with FGFR1 amplification: A singleâ€arm, phase 2 study. Cancer, 2016, 122, 3024-3031.	4.1	72
67	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 2575-2587.	7.0	71
68	A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib. Journal of Thoracic Oncology, 2016, 11, e55-e58.	1.1	70
69	Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1647-1654.	2.5	69
70	Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements. PLoS ONE, 2014, 9, e103333.	2.5	68
71	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1613-1623.	2.5	66
72	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-NaÃ¯ve and Solvent-Frontâ€“Mutant ROS1-Rearranged Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3287-3295.	7.0	66

#	Article	IF	Citations
73	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. , 2019, 7, 339.		65
74	Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stageâ€“SCLC: Results From the Phase 3 MERU Study. Journal of Thoracic Oncology, 2021, 16, 1570-1581.	1.1	65
75	Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Nonâ€“Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clinical Cancer Research, 2021, 27, 4160-4167.	7.0	64
76	Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer, 2014, 83, 389-395.	2.0	63
77	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer, 2015, 121, 2612-2617.	4.1	63
78	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncology, 2021, 17, 1143-1153.	2.4	63
79	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. Journal of Clinical Oncology, 2017, 35, 2020-2020.	1.6	63
80	High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma. Clinical Cancer Research, 2012, 18, 1760-1768.	7.0	60
81	Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience. Yonsei Medical Journal, 2012, 53, 352.	2.2	60
82	Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer, 2013, 80, 249-255.	2.0	60
83	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)â€“Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. Journal of Thoracic Oncology, 2019, 14, 1255-1265.	1.1	59
84	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. Journal of Clinical Oncology, 2016, 34, 9002-9002.	1.6	59
85	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. Journal of Clinical Oncology, 2019, 37, 9011-9011.	1.6	58
86	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9515-9515.	1.6	57
87	Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer, 2009, 63, 106-110.	2.0	56
88	Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. Clinical Cancer Research, 2015, 21, 544-552.	7.0	56
89	Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naÃ¯ve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.. Journal of Clinical Oncology, 2021, 39, 9006-9006.	1.6	55
90	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9512-9512.	1.6	54

#	Article	IF	Citations
91	Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Letters, 2010, 296, 150-159.	7.2	53
92	Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung Cancer, 2014, 84, 196-202.	2.0	53
93	Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e123-e132.	2.6	53
94	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Annals of Oncology, 2021, 32, 395-403.	1.2	53
95	Elevated Serum C-Reactive Protein as a Prognostic Marker in Small Cell Lung Cancer. Yonsei Medical Journal, 2012, 53, 111.	2.2	52
96	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget, 2016, 7, 10547-10556.	1.8	52
97	Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clinical Cancer Research, 2022, 28, 1117-1126.	7.0	52
98	Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 4397-4409.	7.0	49
99	Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer, 2017, 113, 106-114.	2.0	48
100	Bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
101	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. Cancer Research and Treatment, 2019, 51, 300-312.	3.0	48
102	Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer, 2016, 102, 82-88.	2.0	46
103	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. European Journal of Cancer, 2020, 125, 49-57.	2.8	45
104	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology, 2018, 36, 9043-9043.	1.6	45
105	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget, 2016, 7, 36311-36320.	1.8	44
106	MARIPOSA: phase 3 study of first-line amivantamabÂ+Âlazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncology, 2022, 18, 639-647.	2.4	44
107	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Scientific Reports, 2020, 10, 9050.	3.3	43
108	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2022, 17, 558-567.	1.1	43

#	Article	IF	Citations
109	An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. European Journal of Cancer, 2015, 51, 1588-1595.	2.8	42
110	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. Cancer Research, 2018, 78, 3350-3362.	0.9	42
111	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. Future Oncology, 2019, 15, 3003-3014.	2.4	42
112	Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer. Annals of Thoracic Surgery, 2011, 91, 344-348.	1.3	41
113	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget, 2016, 7, 24172-24178.	1.8	41
114	Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer, 2014, 83, 374-382.	2.0	40
115	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK â€rearranged lung cancer. EMBO Molecular Medicine, 2019, 11, e10581.	6.9	40
116	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.. Journal of Clinical Oncology, 2019, 37, 9020-9020.	1.6	39
117	Clinical and Echocardiographic Characteristics of Pericardial Effusion in Patients Who Underwent Echocardiographically Guided Pericardiocentesis: Yonsei Cardiovascular Center Experience, 1993-2003. Yonsei Medical Journal, 2004, 45, 462.	2.2	38
118	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Supportive Care in Cancer, 2013, 21, 1751-1759.	2.2	38
119	Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers. Genome Medicine, 2014, 6, 18.	8.2	37
120	Treatment options for EGFR mutant NSCLC with CNS involvementâ€"Can patients BLOOM with the use of next generation EGFR TKIs?. Lung Cancer, 2017, 108, 29-37.	2.0	37
121	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1095-1102.	3.7	37
122	Updated survival of patients (pts) with previously treated BRAF V600Eâ€"mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.. Journal of Clinical Oncology, 2017, 35, 9075-9075.	1.6	37
123	The prognostic factors of resected non-small cell lung cancer with chest wall invasion. World Journal of Surgical Oncology, 2012, 10, 9.	1.9	36
124	Cancer in Patients on Chronic Dialysis in Korea. Journal of Korean Medical Science, 2009, 24, S95.	2.5	35
125	Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clinical Lung Cancer, 2020, 21, e84-e88.	2.6	35
126	Amivantamab and lazertinib in patients with EGFR-mutant nonâ€"small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.. Journal of Clinical Oncology, 2022, 40, 9006-9006.	1.6	34

#	Article	IF	Citations
127	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Experimental and Therapeutic Medicine, 2011, 2, 685-693.	1.8	33
128	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.. Journal of Clinical Oncology, 2020, 38, 3605-3605.	1.6	33
129	Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. Lung Cancer, 2019, 136, 30-36.	2.0	32
130	Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Lung Cancer, 2019, 127, 112-121.	2.0	31
131	Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clinical Lung Cancer, 2021, 22, 601-606.	2.6	31
132	Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. Molecular Cancer Therapeutics, 2020, 19, 2298-2307.	4.1	30
133	The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2020, 12, 6426-6434.	1.4	30
134	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 2562-2572.	1.8	30
135	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1937-1944.	2.5	29
136	Three-year overall survival update from the PACIFIC trial.. Journal of Clinical Oncology, 2019, 37, 8526-8526.	1.6	29
137	Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. Journal of Thoracic Oncology, 2022, 17, 718-723.	1.1	29
138	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncology, The, 2009, 10, 1102-1110.	10.7	28
139	The promise of bispecific antibodies: Clinical applications and challenges. Cancer Treatment Reviews, 2021, 99, 102240.	7.7	28
140	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology, 2013, 31, 8028-8028.	1.6	28
141	A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2019, 37, 4027-4027.	1.6	28
142	PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 30691-30701.	1.8	28
143	Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. JCI Insight, 2020, 5, .	5.0	27
144	BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. Journal of Clinical Oncology, 2016, 34, 9055-9055.	1.6	27

#	Article	IF	Citations
145	Three-Year Follow-Up and Responseâ€“Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). Clinical Cancer Research, 2022, 28, 3277-3286.	7.0	27
146	A Carcinoembryonic Antigen-Secreting Adenocarcinoma Arising in Tailgut Cyst : Clinical Implications of Carcinoembryonic Antigen. Yonsei Medical Journal, 2005, 46, 555.	2.2	26
147	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Scientific Reports, 2016, 6, 19552.	3.3	26
148	Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head and Neck, 2018, 40, 55-62.	2.0	26
149	Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology, 2009, 65, 27-32.	2.3	25
150	Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of Thoracic Oncology, 2015, 10, 1221-1228.	1.1	25
151	Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. Lung Cancer, 2019, 131, 139-146.	2.0	25
152	Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.. Journal of Clinical Oncology, 2019, 37, 3017-3017.	1.6	25
153	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung Cancer, 2019, 134, 46-51.	2.0	24
154	Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).. Journal of Clinical Oncology, 2020, 38, 9505-9505.	1.6	24
155	EGFRPolymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated withEGFR-TKI. Yonsei Medical Journal, 2012, 53, 1128.	2.2	23
156	RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-ÎºB-mediated ERK reactivation. Cell Death and Disease, 2018, 9, 587.	6.3	23
157	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. Lung Cancer, 2018, 124, 168-178.	2.0	23
158	Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer. Cancer Letters, 2019, 466, 23-34.	7.2	23
159	Real-World Analysis of the Efficacy of Rebiopsy andEGFRMutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2019, 60, 525.	2.2	23
160	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stageÂsmall-cell lung cancer: a single-center experience. Cancer Immunology, Immunotherapy, 2022, 71, 1093-1101.	4.2	23
161	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget, 2017, 8, 65111-65122.	1.8	23
162	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer, 2018, 122, 234-242.	2.0	22

#	Article	IF	Citations
163	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72.	2.0	22
164	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology, 2013, 31, 8027-8027.	1.6	22
165	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. Journal of Clinical Oncology, 2014, 32, 8051-8051.	1.6	22
166	Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. Nuclear Medicine and Molecular Imaging, 2012, 46, 169-175.	1.0	21
167	A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 665-671.	2.3	21
168	Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma. Technology in Cancer Research and Treatment, 2016, 15, 122-129.	1.9	21
169	Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma. Oral Oncology, 2017, 75, 16-21.	1.5	21
170	Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK â€“Positive Human Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 491-500.	1.1	21
171	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	2.0	21
172	Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2012, 7, 731-736.	1.1	20
173	Alteration status and prognostic value of MET in head and neck squamous cell carcinoma. Journal of Cancer, 2016, 7, 2197-2206.	2.5	20
174	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. Journal of Clinical Oncology, 2019, 37, 9016-9016.	1.6	20
175	Primary Idiopathic Chylopericardium Associated with Cervicomediastinal Cystic Hygroma. Yonsei Medical Journal, 2005, 46, 439.	2.2	19
176	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2015, 14, 2238-2248.	4.1	19
177	Ei24-deficiency attenuates protein kinase CÎ± signaling and skin carcinogenesis in mice. International Journal of Biochemistry and Cell Biology, 2012, 44, 1887-1896.	2.8	18
178	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. Future Oncology, 2013, 9, 377-386.	2.4	18
179	The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences inKRASMutations in Korean Patients with Lung Adenocarcinoma. Yonsei Medical Journal, 2013, 54, 865.	2.2	18
180	Profiling of proteinâ€“protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nature Biomedical Engineering, 2018, 2, 239-253.	22.5	18

#	Article	IF	Citations
181	A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. Annals of Surgical Oncology, 2018, 25, 864-871.	1.5	18
182	Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity. Head and Neck, 2019, 41, 198-207.	2.0	18
183	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. Scientific Reports, 2019, 9, 19909.	3.3	18
184	Mouseâ€“human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. British Journal of Cancer, 2020, 123, 1720-1729.	6.4	18
185	Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.. Journal of Clinical Oncology, 2017, 35, 9536-9536.	1.6	18
186	A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2013, 79, 270-275.	2.0	17
187	Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma. Apmis, 2017, 125, 974-984.	2.0	17
188	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. British Journal of Cancer, 2020, 122, 1649-1660.	6.4	17
189	Olmutinib in T790Mâ€positive nonâ€“small cell lung cancer after failure of firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 2021, 127, 1407-1416.	4.1	17
190	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naÃ¯ve, EGFRm NSCLC with CNS metastases.. Journal of Clinical Oncology, 2017, 35, 2006-2006.	1.6	17
191	Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.. Journal of Clinical Oncology, 2020, 38, 9516-9516.	1.6	17
192	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization. Oncotarget, 2017, 8, 87234-87243.	1.8	17
193	The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges. Frontiers in Oncology, 2022, 12, 811247.	2.8	17
194	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. , 2020, 8, e000970.		16
195	Clinical decision support algorithm based on machine learning to assess the clinical response to antiâ€programmed death-1 therapy in patients with nonâ€small-cell lung cancer. European Journal of Cancer, 2021, 153, 179-189.	2.8	16
196	Rare Incidence of <i>ROS1</i> Rearrangement in Cholangiocarcinoma. Cancer Research and Treatment, 2017, 49, 185-192.	3.0	16
197	Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. Current Oncology, 2022, 29, 2154-2164.	2.2	16
198	Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients. Oncology, 2010, 79, 293-300.	1.9	15

#	Article	IF	Citations
199	Allosteric Inhibitor TREAâ€0236 Containing Nonâ€hydrolysable Quinazolineâ€4â€one for EGFR T790M/C797S Mutants Inhibition. Bulletin of the Korean Chemical Society, 2018, 39, 895-898.	1.9	15
200	High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. Scientific Reports, 2019, 9, 20197.	3.3	15
201	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). Journal of Pathology and Translational Medicine, 2018, 52, 148-156.	1.1	15
202	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusionâ€“Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100332.	1.1	15
203	Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. Lung Cancer, 2010, 70, 77-81.	2.0	14
204	Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung. Yonsei Medical Journal, 2013, 54, 854.	2.2	14
205	Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer. BMC Cancer, 2020, 20, 316.	2.6	14
206	Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, 3584-3584.	1.6	14
207	Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective. Cancer Research and Treatment, 2017, 49, 168-177.	3.0	14
208	Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9013-9013.	1.6	14
209	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 157-165.	2.3	13
210	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer, 2016, 93, 1-8.	2.0	13
211	Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node Metastasis. Anticancer Research, 2019, 39, 6307-6316.	1.1	13
212	Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma. BMC Cancer, 2020, 20, 348.	2.6	13
213	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 44971-44984.	1.8	13
214	Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer, 2008, 8, 8.	2.6	12
215	Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells. Lung Cancer, 2015, 90, 175-181.	2.0	12
216	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. PLoS ONE, 2019, 14, e0224379.	2.5	12

#	Article	IF	Citations
217	CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2021, 39, TPS9132-TPS9132.	1.6	12
218	Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC). Cancer Research, 2021, 81, 1467-1467.	0.9	12
219	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. Journal of Clinical Oncology, 2017, 35, 2069-2069.	1.6	12
220	A Pilot Study of Trans-Arterial Injection of¹⁶⁶Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma. Yonsei Medical Journal, 2005, 46, 799.	2.2	11
221	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemotherapy and Pharmacology, 2007, 61, 309-313.	2.3	11
222	The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. Lung Cancer, 2008, 60, 393-400.	2.0	11
223	Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer, 2013, 80, 313-318.	2.0	11
224	Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Pharmacogenetics and Genomics, 2016, 26, 116-125.	1.5	11
225	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer, 2017, 106, 76-82.	2.0	11
226	A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget, 2017, 8, 15943-15951.	1.8	11
227	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9124-TPS9124.	1.6	11
228	Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.. Journal of Clinical Oncology, 2022, 40, 8541-8541.	1.6	11
229	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 75-81.	2.3	10
230	A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 539-548.	2.3	10
231	Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 873-880.	2.3	10
232	Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study. Anticancer Research, 2019, 39, 1403-1409.	1.1	10
233	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. Cancer, 2020, 126, 4521-4531.	4.1	10
234	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Nonâ€“Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer, 2021, 22, 301-312.e8.	2.6	10

#	Article	IF	Citations
235	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9036-9036.	1.6	10
236	The Clinical Usefulness of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma. Cancer Research and Treatment, 2016, 48, 928-941.	3.0	10
237	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment, 2020, 52, 1112-1119.	3.0	10
238	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210791.	3.2	10
239	Subacute Bacterial Endocarditis Associated with Upper Endoscopy. Yonsei Medical Journal, 2004, 45, 936.	2.2	9
240	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer, 2017, 112, 195-199.	2.0	9
241	Real-world use of osimertinib in nonâ€“small cell lung cancer: ASTRIS study Korean subgroup analysis. Current Medical Research and Opinion, 2020, 36, 477-482.	1.9	9
242	NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.. Journal of Clinical Oncology, 2014, 32, 8036-8036.	1.6	9
243	Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection. Cancer Research and Treatment, 2019, 51, 1052-1063.	3.0	9
244	Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous nonâ€“small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).. Journal of Clinical Oncology, 2022, 40, 9039-9039.	1.6	9
245	Weekly 5â€fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Head and Neck, 2010, 32, 235-243.	2.0	8
246	The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. Lung Cancer, 2015, 88, 325-331.	2.0	8
247	EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600Eâ€“Mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 2016, 15, 1627-1636.	4.1	8
248	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. Journal of Clinical Oncology, 2021, 39, 204-204.	1.6	8
249	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Cancer Medicine, 2021, 10, 7012-7020.	2.8	8
250	Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.. Journal of Clinical Oncology, 2016, 34, 9014-9014.	1.6	8
251	TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.. Journal of Clinical Oncology, 2020, 38, TPS9637-TPS9637.	1.6	8
252	ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. Lung Cancer, 2016, 95, 57-64.	2.0	7

#	Article	IF	Citations
253	Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. Lung Cancer, 2017, 111, 79-83.	2.0	7
254	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Lung Cancer, 2018, 119, 36-41.	2.0	7
255	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancers, 2021, 13, 3096.	3.7	7
256	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9558-9558.	1.6	7
257	Patritumab Deruxtecan: Paving the Way for EGFR-TKIâ€“Resistant NSCLC. Cancer Discovery, 2022, 12, 16-19.	9.4	7
258	Predicting treatment outcomes using ¹⁸F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	3.2	7
259	Structureâ€“Activity Relationship Study of 2,4â€Ðianilinopyrimidine Containing Methanesulfonamide (TREâ€Ð069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment. Bulletin of the Korean Chemical Society, 2017, 38, 1353-1357.	1.9	6
260	DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway. Experimental and Molecular Medicine, 2021, 53, 643-653.	7.7	6
261	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. JTO Clinical and Research Reports, 2021, 2, 100224.	1.1	6
262	Antiâ€“cytotoxic T-lymphocyteâ€“associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. Lung Cancer, 2021, 159, 162-170.	2.0	6
263	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS8570-TPS8570.	1.6	6
264	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9075-TPS9075.	1.6	6
265	Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme. PLoS ONE, 2015, 10, e0137678.	2.5	6
266	Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncology Reports, 2006, 15, 621-7.	2.6	6
267	SKIâ€Cân801, an AXL kinase inhibitor, blocks metastasis through inducing antiâ€tumor immune responses and potentiates antiâ€PDâ€1 therapy in mouse cancer models. Clinical and Translational Immunology, 2022, 11, e1364.	3.8	6
268	A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2022, 31, 747-757.	4.1	6
269	Tumor <scp>MET</scp> expression profile predicts the outcome of nonâ€small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Thoracic Cancer, 2014, 5, 517-524.	1.9	5
270	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. Cancer Chemotherapy and Pharmacology, 2019, 84, 405-414.	2.3	5

#	Article	IF	Citations
271	Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.. Journal of Clinical Oncology, 2021, 39, 168-168.	1.6	5
272	Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.. Journal of Clinical Oncology, 2019, 37, e20661-e20661.	1.6	5
273	Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study. Radiation Oncology Journal, 2017, 35, 153-162.	1.5	5
274	A Case of Synchronous Squamous Cell Carcinoma in the Esophagus and Stomach. Gut and Liver, 2012, 6, 118-121.	2.9	5
275	Antibodyâ€“Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Nonâ€“Small Cell Lung Cancer. Cancer Research, 2022, 82, 18-20.	0.9	5
276	Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial. Molecular Cancer Therapeutics, 2021, 20, P02-01-P02-01.	4.1	5
277	The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2010, 51, 1.	2.2	4
278	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2012, 70, 539-546.	2.3	4
279	Induction docetaxel and Sâ€1 followed by concomitant radiotherapy with lowâ€dose daily cisplatin in locally advanced head and neck carcinoma. Head and Neck, 2016, 38, E1653-9.	2.0	4
280	NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 11231.	3.3	4
281	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2021, 39, 6020-6020.	1.6	4
282	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291.	3.0	4
283	470â€…A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59). , 2021, 9, A499-A499.		4
284	Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study. Cancer Research, 2022, 82, LB078-LB078.	0.9	4
285	Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer. Journal of Neuro-Oncology, 2017, 132, 333-340.	2.9	3
286	Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib. JTO Clinical and Research Reports, 2021, 2, 100180.	1.1	3
287	Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. Cancers, 2021, 13, 3681.	3.7	3
288	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2021, 2, 100206.	1.1	3

#	Article	IF	Citations
289	Durvalumab in â‰¥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.. Journal of Clinical Oncology, 2018, 36, 9058-9058.	1.6	3
290	First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.. Journal of Clinical Oncology, 2019, 37, 9054-9054.	1.6	3
291	Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.. Journal of Clinical Oncology, 2020, 38, 9556-9556.	1.6	3
292	Abstract CT198: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study. Cancer Research, 2022, 82, CT198-CT198.	0.9	3
293	A man with recurrent hypovolemic shock on antiâ€“programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy. European Journal of Cancer, 2018, 104, 104-107.	2.8	2
294	Can We Prevent Resistance to Osimertinib? Combination or Sequential. Journal of Thoracic Oncology, 2018, 13, 877-879.	1.1	2
295	Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate. PLoS ONE, 2019, 14, e0214291.	2.5	2
296	Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients. Scientific Reports, 2021, 11, 7435.	3.3	2
297	Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?. Journal of Thoracic Oncology, 2021, 16, 709-711.	1.1	2
298	Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.. Journal of Clinical Oncology, 2021, 39, TPS3150-TPS3150.	1.6	2
299	Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd-generation EGFR-TKI, in EGFR-mutant NSCLC. Cancer Research, 2021, 81, 1106-1106.	0.9	2
300	Patient-reported outcomes (PROs) with first-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.	1.6	2
301	Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.. Journal of Clinical Oncology, 2019, 37, 9037-9037.	1.6	2
302	281â€…JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC). , 2020, , .		2
303	Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-NaÃ¯ve Patients with ALK+ Nonâ€“Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. Cancer Research and Treatment, 2023, 55, 83-93.	3.0	2
304	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. Acta OncolÃ³gica, 2007, 46, 547-549.	1.8	1
305	Identification of TREâ€130 as Reversible Inhibitor of Panâ€EGFR Mutants while Sparing EGFR Wildâ€Type Activity. Bulletin of the Korean Chemical Society, 2019, 40, 1222-1225.	1.9	1
306	Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.. Journal of Clinical Oncology, 2021, 39, TPS8580-TPS8580.	1.6	1

#	Article	IF	Citations
307	Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.. Journal of Clinical Oncology, 2019, 37, 2558-2558.	1.6	1
308	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2020, 38, 9601-9601.	1.6	1
309	Dynamic changes in circulating PD-1⁺CD8⁺ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e21690-e21690.	1.6	1
310	A Case of Lactic Acidosis Caused by Stavudine in an AIDS Patient. Korean Journal of Internal Medicine, 2004, 19, 66-69.	1.7	1
311	Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naÃ¯ve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.. Journal of Clinical Oncology, 2016, 34, 9081-9081.	1.6	1
312	A machine learning based prediction model of anti-PD-1 therapy response using noninvasive clinical information and blood markers of lung cancer patients.. Journal of Clinical Oncology, 2019, 37, e14138-e14138.	1.6	1
313	Contemporary management and associated outcomes of 3,151 patients with stage III non-small cell lung cancer (NSCLC) in a real-world setting: Results of KINDLE, a multicountry observational study.. Journal of Clinical Oncology, 2020, 38, 9043-9043.	1.6	1
314	Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL).. Journal of Clinical Oncology, 2020, 38, 9575-9575.	1.6	1
315	Abstract LB515A: A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations. Cancer Research, 2022, 82, LB515A-LB515A.	0.9	1
316	Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.. Journal of Clinical Oncology, 2022, 40, 6072-6072.	1.6	1
317	Complete Response of Recurrent Squamous Cell Carcinoma of the Lung: Dose the Dose Matter?. Journal of Thoracic Oncology, 2009, 4, 141-142.	1.1	0
318	Multiple target loci assembly sequencing (mTAS). Analytical Biochemistry, 2011, 415, 218-220.	2.4	0
319	A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant ActivatingEGFRMutation andROS1Rearrangement. The Ewha Medical Journal, 2014, 37, 46.	0.2	0
320	Copy Number Abnormalities and Gene Fusions in Lung Cancer. , 2018, , 82-94.e4.		0
321	Abstract 1787: YH29407, a novel IDO1 inhibitor, enhances the anti-tumor effects through increased tumor-reactive T cell functions in solid tumor. , 2021, , .		0
322	Abstract CT255: Canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer: CANOPY-A trial. , 2021, , .		0
323	Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D. , 2021, , .		0
324	Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2012, 30, e18092-e18092.	1.6	0

#	Article	IF	Citations
325	A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.. Journal of Clinical Oncology, 2014, 32, 4083-4083.	1.6	0
326	Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative.. Journal of Clinical Oncology, 2016, 34, e20575-e20575.	1.6	0
327	Defining the immunologic phenotypes and their prognostic impacts on head and neck squamous cell cancer (HNSCC).. Journal of Clinical Oncology, 2016, 34, 6055-6055.	1.6	0
328	Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. Journal of Clinical Oncology, 2017, 35, 92-92.	1.6	0
329	Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	0
330	Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2018, 36, e18015-e18015.	1.6	0
331	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.. Journal of Clinical Oncology, 2019, 37, 3046-3046.	1.6	0
332	Preclinical characterization and efficacy of 4R9, a novel immune checkpoint blockade targeting CEACAM1 for cancer therapy.. Journal of Clinical Oncology, 2019, 37, e14155-e14155.	1.6	0
333	Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) patients from East Asia.. Journal of Clinical Oncology, 2020, 38, e21608-e21608.	1.6	0
334	572â€…Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkineâ„¢ potentiates anti-cancer effects in preclinical cancer models. , 2020, , .		0
335	Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC. , 0, , .		0
336	Abstract 5481: Combination therapy with anti-PD-1 and YH29407, a novel IDO1 inhibitor, enhances T cell-mediated antitumor immunity in MC38 tumor-bearing mice. Cancer Research, 2022, 82, 5481-5481.	0.9	0
337	AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusionâ€“positive advanced/metastatic NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9159-TPS9159.	1.6	0
338	Abstract 3527: Novel bacteria strains, CJRS-10671 and CJRS-10672, enhance anti-tumor efficacy in LLC1 syngeneic model and humanized PDX mice model. Cancer Research, 2022, 82, 3527-3527.	0.9	0
339	Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research, 2022, 82, CT561-CT561.	0.9	0
340	Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs. Cancer Research, 2022, 82, LB544-LB544.	0.9	0